Future Neurology “Real-world insights into idiopathic hypersomnia symptoms, treatments, and quality of life from the ARISE study: a Plain Language Summary of Publication”

Alkermes Announces Positive Topline Results From REVITALYZ℠ Phase 3 Study Evaluating LUMRYZ® (sodium oxybate) Extended-Release in Adults With Idiopathic Hypersomnia

Wake Up Narcolepsy 2026 National Summit Recap

Institute for Clinical and Economic Review Releases Evidence Report on Treatment for Narcolepsy

Alkermes to Present Additional Data From Vibrance-1 Phase 2 Study of Alixorexton in Patients with Narcolepsy Type 1 at the American Academy of Neurology (AAN) 2026 Annual Meeting

2026 Narcolepsy Family Weekend Recap

Alkermes Announces Initiation of Phase 3 Brilliance Studies Evaluating Alixorexton for the Treatment of Narcolepsy Type 1 and Type 2

Lilly to acquire Centessa Pharmaceuticals to advance treatments for sleep-wake disorders

Join Us for April’s Brown Bag Webinar – Navigating Narcolepsy and Pregnancy

Harmony Biosciences Receives U.S. Food and Drug Administration Approval for WAKIX® (pitolisant) for the Treatment of Cataplexy in Pediatric Narcolepsy